Dasatinib Tops Imatinib for Ph + Acute Lymphoblastic Leukemia

Four - year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Pharmacy, Journal, Source Type: news